Novavax awaits one more signature from the CDC before it can be used for public use.
“Today’s authorization offers adults in the United States who have not yet received a COVID-19 vaccine another option that meets the FDA’s rigorous standards for safety, effectiveness and manufacturing quality needed to support emergency use authorization,” FDA Commissioner Robert Califf, MD, said in a statement.
Barely two-thirds of the nation is fully vaccinated against COVID-19, according to CDC estimates.
The two-dose adjuvanted series — which is an ingredient typical for vaccines intended to boost immune responses — has a 90.4 percent efficacy rate in adults.
Two days before the authorization, the federal government ordered 3.2 million doses of the vaccine in anticipation of the FDA giving the OK.
